Treatment of ABC-DLBCL cells with ibrutinib decreased IRF4 protein, reduced NF-κB signaling, increased interferon (IFN) β production, and also synergized with lenalidomide in killing lymphoma cells in vitro and in mouse model [31]. Here, NFKB1 is linked to aneurysmal bone cyst.